• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

迷幻药物治疗物质使用障碍和物质滥用:混合方法系统评价。

Psychedelic Treatments for Substance Use Disorder and Substance Misuse: A Mixed Methods Systematic Review.

机构信息

School of Health and Psychological Sciences, City, University of London, England, London, UK.

出版信息

J Psychoactive Drugs. 2023 Nov-Dec;55(5):612-630. doi: 10.1080/02791072.2023.2190319. Epub 2023 Mar 18.

DOI:10.1080/02791072.2023.2190319
PMID:36933948
Abstract

Renewed interest in psychedelic substances in the 21 century has seen the exploration of psychedelic treatments for various psychiatric disorders including substance use disorder (SUD). This review aimed to assess the effectiveness of psychedelic treatments for people with SUD and those falling below diagnostic thresholds (i.e. substance misuse). We systematically searched 11 databases, trial registries, and psychedelic organization websites for empirical studies examining adults undergoing psychedelic treatment for SUD or substance misuse, published in the English language, between 2000 and 2021. Seven studies investigating treatment using psilocybin, ibogaine, and ayahuasca, alone or adjunct with psychotherapy reported across 10 papers were included. Measures of abstinence, substance use, psychological and psychosocial outcomes, craving, and withdrawal reported positive results, however, this data was scarce among studies examining a wide range of addictions including opioid, nicotine, alcohol, cocaine and unspecified substance. The qualitative synthesis from three studies described subjective experience of psychedelic-assisted treatments enhanced self-awareness, insight, and confidence. At present, there is no sufficient research evidence to suggest effectiveness of any of the psychedelics on any specific substance use disorder or substance misuse. Further research using rigorous effectiveness evaluation methods with larger sample sizes and longer-term follow-up is required.

摘要

21 世纪,人们对迷幻物质重新产生了兴趣,迷幻物质治疗各种精神疾病的探索也随之展开,包括物质使用障碍(SUD)。本综述旨在评估迷幻物质治疗 SUD 患者和低于诊断阈值(即物质滥用)患者的有效性。我们系统地检索了 11 个数据库、试验登记处和迷幻药物组织网站,以寻找 2000 年至 2021 年间发表的、用英文撰写的、关于成年人接受迷幻物质治疗 SUD 或物质滥用的实证研究。共有 10 篇论文报告了 7 项使用裸盖菇素、伊博加因和死藤水进行治疗的研究,这些研究单独或联合心理治疗进行。关于戒断、物质使用、心理和社会心理结果、渴望和戒断的措施报告了积极的结果,然而,在研究各种成瘾物质(包括阿片类药物、尼古丁、酒精、可卡因和未指明的物质)时,这种数据非常缺乏。来自三项研究的定性综合描述了迷幻辅助治疗增强了自我意识、洞察力和信心的主观体验。目前,没有足够的研究证据表明任何迷幻物质对任何特定的物质使用障碍或物质滥用都有效。需要使用更严格的有效性评估方法、更大的样本量和更长的随访时间进行进一步的研究。

相似文献

1
Psychedelic Treatments for Substance Use Disorder and Substance Misuse: A Mixed Methods Systematic Review.迷幻药物治疗物质使用障碍和物质滥用:混合方法系统评价。
J Psychoactive Drugs. 2023 Nov-Dec;55(5):612-630. doi: 10.1080/02791072.2023.2190319. Epub 2023 Mar 18.
2
Psychological therapies for post-traumatic stress disorder and comorbid substance use disorder.创伤后应激障碍及共病物质使用障碍的心理治疗
Cochrane Database Syst Rev. 2016 Apr 4;4(4):CD010204. doi: 10.1002/14651858.CD010204.pub2.
3
Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis.比较裸盖菇素、麦角酸二乙基酰胺、3,4-亚甲二氧基甲基苯丙胺、死藤水和依地普仑单药治疗抑郁症状的疗效:系统评价和贝叶斯网络荟萃分析。
BMJ. 2024 Aug 21;386:e078607. doi: 10.1136/bmj-2023-078607.
4
Psychosocial interventions for cannabis use disorder.针对大麻使用障碍的心理社会干预措施。
Cochrane Database Syst Rev. 2016 May 5;2016(5):CD005336. doi: 10.1002/14651858.CD005336.pub4.
5
Music therapy for people with substance use disorders.音乐治疗物质使用障碍人群。
Cochrane Database Syst Rev. 2022 May 9;5(5):CD012576. doi: 10.1002/14651858.CD012576.pub3.
6
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.加拿大情绪和焦虑治疗网络(CANMAT)工作组报告:治疗重度抑郁症的血清素致幻药物治疗。
Can J Psychiatry. 2023 Jan;68(1):5-21. doi: 10.1177/07067437221111371. Epub 2022 Aug 17.
7
Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.5-羟色胺能致幻剂治疗心境障碍、焦虑症和物质使用障碍的疗效、耐受性和安全性:系统评价的系统评价。
Expert Rev Clin Pharmacol. 2018 Sep;11(9):889-902. doi: 10.1080/17512433.2018.1511424. Epub 2018 Aug 23.
8
Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents.心理治疗与抗抑郁药物单独及联合使用治疗儿童和青少年抑郁症
Cochrane Database Syst Rev. 2012 Nov 14;11:CD008324. doi: 10.1002/14651858.CD008324.pub2.
9
Psychological therapies for treatment-resistant depression in adults.成人难治性抑郁症的心理治疗
Cochrane Database Syst Rev. 2018 May 14;5(5):CD010558. doi: 10.1002/14651858.CD010558.pub2.
10
Electronic cigarettes for smoking cessation.电子烟戒烟。
Cochrane Database Syst Rev. 2021 Sep 14;9(9):CD010216. doi: 10.1002/14651858.CD010216.pub6.

引用本文的文献

1
Harnessing neuroplasticity with psychoplastogens: the essential role of psychotherapy in psychedelic treatment optimization.利用心理塑型剂激发神经可塑性:心理治疗在优化迷幻药治疗中的关键作用。
Front Psychiatry. 2025 Apr 8;16:1565852. doi: 10.3389/fpsyt.2025.1565852. eCollection 2025.
2
The therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies.迷幻药治疗阿片类物质使用障碍的疗效:临床研究的系统评价
Psychiatry Res. 2025 Jun;348:116446. doi: 10.1016/j.psychres.2025.116446. Epub 2025 Mar 15.
3
A Narrative Review of Old and Emerging Treatment Modalities for Substance Use Disorders.
物质使用障碍的传统与新兴治疗方式叙事综述
Cureus. 2024 Dec 9;16(12):e75395. doi: 10.7759/cureus.75395. eCollection 2024 Dec.
4
The potential of non-psychedelic 5-HT2A agents in the treatment of substance use disorders: a narrative review of the clinical literature.非致幻性5-羟色胺2A受体(5-HT2A)药物在治疗物质使用障碍中的潜力:临床文献的叙述性综述
Expert Opin Pharmacother. 2025 Feb;26(2):133-146. doi: 10.1080/14656566.2024.2446623. Epub 2024 Dec 26.